We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B Turnover 46.34%
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
-10.1%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$792M
AUM Growth
-$198M
Cap. Flow
-$87.5M
Cap. Flow %
-11.05%
Top 10 Hldgs %
71.73%
Holding
49
New
10
Increased
7
Reduced
13
Closed
11
Avg Time Held Equity + Options
0.9 years
Top 10 Avg Time Held Equity + Options
1 year
Top 20 Avg Time Held Equity + Options
0.8 years
Avg Time Held Equity only
0.9 years
Top 10 Avg Time Held Equity only
1.1 years
Top 20 Avg Time Held Equity only
0.8 years

Top Buys

Rank Stock Value
1
PRTA icon
Prothena Corp
PRTA
+$77.3M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$22.4M
3
SLDB icon
Solid Biosciences
SLDB
+$19M
4
XCUR icon
Exicure
XCUR
+$14.1M
5
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$10.1M

Top Sells

Rank Stock Value
1
CRSP icon
CRISPR Therapeutics
CRSP
+$75.8M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$51.9M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$23.7M
4
KURA icon
Kura Oncology
KURA
+$22M
5
GOSS icon
Gossamer Bio
GOSS
+$15.4M

Sector Composition

Rank Sector Weight
1 Healthcare 94.64%
2 Miscellaneous 5.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
MRTX
26
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$3.44M 0.44%
44,221
-553,490
-93% -$51.9M
2018 Q4
3 quarters
MRUS icon
27
DELISTED
Merus
MRUS
$2.95M 0.37%
+165,600
New +$2.72M
2019 Q3
0 quarters
RARE icon
28
Ultragenyx Pharmaceutical
RARE
$1.5B
$2.63M 0.33%
61,554
-436,345
-88% -$23.7M
2019 Q1
2 quarters
SURF
29
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$2.2M 0.28%
1,548,888
-763,800
-33% -$1.67M
2018 Q2
5 quarters
RUBY
30
DELISTED
Rubius Therapeutics, Inc
RUBY
$2.04M 0.26%
260,152
-203,000
-44% -$2.37M
2018 Q3
4 quarters
VCEL icon
31
Vericel Corp
VCEL
$2.1B
$1.98M 0.25%
131,001
– –
2019 Q1
2 quarters
IGMS icon
32
DELISTED
IGM Biosciences
IGMS
$1.77M 0.22%
+100,000
New +$2.02M
2019 Q3
0 quarters
LRMR icon
33
Larimar Therapeutics
LRMR
$207M
$1.44M 0.18%
+162,042
New +$1.78M
2019 Q3
0 quarters
IRLA
34
IRulya Therapeutics Inc. Common Stock
IRLA
$33.8M
$1.25M 0.16%
+250
New +$1.54M
2019 Q3
0 quarters
ASMB icon
35
Assembly Biosciences
ASMB
$419M
$950K 0.12%
+8,050
New +$1.22M
2019 Q3
0 quarters
AUTL icon
36
Autolus Therapeutics
AUTL
$458M
$859K 0.11%
+69,155
New +$914K
2019 Q3
0 quarters
RGLS icon
37
DELISTED
Regulus Therapeutics
RGLS
$755K 0.1%
104,909
-6,202
-6% -$50.5K
2019 Q2
1 quarter
UBX icon
38
DELISTED
Unity Biotechnology
UBX
$314K 0.04%
5,140
-99,310
-95% -$7.03M
2018 Q2
5 quarters
CRSP icon
39
CRISPR Therapeutics
CRSP
$4.98B
– –
-1,610,250
Closed -$75.8M –
GOSS icon
40
Gossamer Bio
GOSS
$54.4M
– –
-9,651
Closed -$15.4M –
KZR icon
41
DELISTED
Kezar Life Sciences
KZR
– –
-58,329
Closed -$4.5M –
MRSN icon
42
DELISTED
Mersana Therapeutics
MRSN
– –
-55,689
Closed -$5.64M –
RYTM icon
43
Rhythm Pharmaceuticals
RYTM
$6.06B
– –
-223,167
Closed -$4.91M –
SYRS icon
44
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
– –
-24,848
Closed -$2.3M –
NGM
45
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
– –
-316,900
Closed -$4.64M –
GMDA
46
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
– –
-52,120
Closed -$265K –
KDNY
47
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-352,284
Closed -$2.71M –
TCRR
48
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
– –
-16,114
Closed -$231K –
ARQL
49
DELISTED
Arqule Inc
ARQL
– –
-1,300,000
Closed -$14.3M –
1
2

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q3 2019 Portfolio in Review

As of Q3 2019, EcoR1 Capital held 49 positions worth $792M, down 20% from $990M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

EcoR1 Capital withdrew a net $87.5M in Q3 2019, closing 11 positions and reducing 13 holdings. Its most notable exit was CRISPR Therapeutics, an estimated $75.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 98% a quarter earlier, followed by Miscellaneous.

Against the trend, EcoR1 Capital opened a new position in Sarepta Therapeutics worth $14.3M.

  • EcoR1 Capital's largest Q3 2019 buy was Sarepta Therapeutics: 189,745 shares worth $14.3M.
  • EcoR1 Capital added most to Prothena Corp in Q3 2019, an estimated $77.3M increase.
  • EcoR1 Capital's biggest Q3 2019 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $51.9M.
  • EcoR1 Capital fully exited CRISPR Therapeutics in Q3 2019, selling an estimated $75.8M.
  • EcoR1 Capital's ten largest holdings make up 72% of its $792M portfolio in Q3 2019.
  • EcoR1 Capital opened 10 new positions and closed 11 in Q3 2019.
  • EcoR1 Capital's portfolio value fell 20% quarter-over-quarter to $792M.

Based on EcoR1 Capital's 13F filing for Q3 2019, filed 14 Nov 2019.